608 related articles for article (PubMed ID: 32383328)
1. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
[TBL] [Abstract][Full Text] [Related]
3. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
4. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Lee SM; Upadhyay S; Lewanski C; Falk S; Skailes G; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Rudd R; Ngai Y; Edwards A; Hackshaw A
Eur J Cancer; 2019 Oct; 120():86-96. PubMed ID: 31499384
[TBL] [Abstract][Full Text] [Related]
5. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
8. Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
Puskas R; Bikov A; Horvath P; Lazar Z; Kunos L; Nagy R; Pinter G; Galffy G
Pathol Oncol Res; 2021; 27():631969. PubMed ID: 34257598
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer.
Chen C; Zhu YH; Huang JA
J Cancer Res Ther; 2018 Jun; 14(Supplement):S336-S340. PubMed ID: 29970686
[TBL] [Abstract][Full Text] [Related]
10. Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma.
Ren X; Zhang Y; Lyu Y; Jin B; Guo H; Wu J; Li X; Liu X
Cancer Biomark; 2019; 26(2):139-150. PubMed ID: 31356196
[TBL] [Abstract][Full Text] [Related]
11. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer.
Li Q; Jiang M; Han X; Yang Z; Shu W; Ding X
J Cancer Res Ther; 2020; 16(2):222-229. PubMed ID: 32474505
[TBL] [Abstract][Full Text] [Related]
13. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen.
Zhao J; Zhao M; Jin B; Yu P; Hu X; Teng Y; Zhang J; Luo Y; Zhang L; Zheng S; Zhou Q; Li H; Liu Y; Qu X
BMC Cancer; 2012 Aug; 12():330. PubMed ID: 22852778
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
15. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Xu CA; Su H; Liu JL; Li L; Zou HW
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
17. Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase.
Buccheri G; Ferrigno D;
Lung Cancer; 2000 Oct; 30(1):37-49. PubMed ID: 11008008
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.
Abbas M; Ahmed A; Khan GJ; Baig MMFA; Naveed M; Mikrani R; Cao T; Naeem S; Shi M; Dingding C
Curr Probl Cancer; 2019 Feb; 43(1):5-17. PubMed ID: 30172422
[TBL] [Abstract][Full Text] [Related]
19. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
